entdoc flashback post Monday, 07/19/10 11:34:05 PM #53989 Hard to believe this was 6 years ago:
"Here's the deal: PPHM's monoclonal antibody Bavituximab has been used now in combination with standard chemotherapy and found to "not interfere" in any way with results of chemo/cancer treatment, but probably actually improves results. PPHMs MAB Bavituximab now has an established safety profile. That is Huge! Huge, and that safety profile is for an inferior grade MAB [e.g. Bavituximab], one made up, in part, of mouse parts which may cause increased levels of allergic reaction. So Bavi may be safely added to standard chemotherapy. "Naked" [unarmed] Bavi was NEVER NEVER intended to be a stand-alone cancer killer. NEVER! But a lagniape that we never imagined is that BAvi is probably an immunological stimulant even when "unarmed" and used in the cancer treatment mix. And that immune boost is documented in severely immunologically crippled advanced cancer cases. But we are not, repeat NOT, in this because Bavi showed some measurable improved survival even unarmed. We, like BMY, are after the biggie: fully-armed a fully humanized MAB cancer bomb. That's the cancer killer. Not chemo. Not naked Bavi. Read my lips: it is fully armed and fully humanized Bavi. BMY has their full-humanized MAB that docks on anti-EGF. PPHM's MAB has a better, more universally applicable cancer docking site, -PS. The science is a done deal. The animal trials are finished. The theory is sound. The patents are there. The strategy is to add two known quantities together to fight cancer, fully-armed and fully human MAB Bavi. It's a no-brainer, that's where we're going. The coup de grace is to move fully armed and fully human Bavi directly into PIIB human trials. That's why we're here. That's when the PPS share kickstarts.
